Anti-Cytochrome p450 2C19 antibody [EPR6577] - BSA and Azide free
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Rabbit Recombinant Monoclonal CP2CJ antibody. Carrier free. Suitable for ICC/IF, IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
View Alternative Names
Cytochrome P450 2C19, (R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CYPIIC17, CYPIIC19, Cytochrome P450-11A, Cytochrome P450-254C, Fenbendazole monooxygenase (4'-hydroxylating), Mephenytoin 4-hydroxylase, CYP2C19
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-Cytochrome p450 2C19 antibody [EPR6577] - BSA and Azide free (AB250812)
This data was developed using ab185213, the same antibody clone in a different buffer formulation.
Immunofluorescent analysis of 4% paraformaldehyde fixed 293 cells labeling Cytochrome P450 2C19 with ab185213 at 1/250 followed by Goat anti rabbit IgG (Alexa Fluor®555) at 1/200 and counterstained with Dapi.
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-Cytochrome p450 2C19 antibody [EPR6577] - BSA and Azide free (AB250812)
This data was developed using ab185213, the same antibody clone in a different buffer formulation.
Intracellular flow cytometric analysis of 2% paraformaldehyde fixed HeLa cells labeling Cytochrome P450 2C19 with ab185213 at 1/240 (red) or Rabbit monoclonal IgG (green) followed by Goat anti rabbit IgG (FITC) at 1/150.
- WB
Supplier Data
Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - BSA and Azide free (AB250812)
This data was developed using ab185213, the same antibody clone in a different buffer formulation.
All lanes:
Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (<a href='/en-us/products/primary-antibodies/cytochrome-p450-2c19-antibody-epr6577-c-terminal-ab185213'>ab185213</a>) at 1/1000 dilution
All lanes:
Human fetal liver lysate at 10 µg
Secondary
All lanes:
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 56 kDa
Observed band size: 52 kDa
false
- IP
Supplier Data
Immunoprecipitation - Anti-Cytochrome p450 2C19 antibody [EPR6577] - BSA and Azide free (AB250812)
This data was developed using ab185213, the same antibody clone in a different buffer formulation.
Immunoprecipitation analysis of 293 cell lysate immunoprecipitated for Cytochrome P450 2C19 using ab185213 at 1/50 dilution (Lane 1). An Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1500 dilution was used as secondary. Lane 2 : PBS instead of 293 lysates.
All lanes:
Immunoprecipitation - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (<a href='/en-us/products/primary-antibodies/cytochrome-p450-2c19-antibody-epr6577-c-terminal-ab185213'>ab185213</a>)
Predicted band size: 56 kDa
Observed band size: 52 kDa
false
- WB
Supplier Data
Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - BSA and Azide free (AB250812)
This data was developed using ab185213, the same antibody clone in a different buffer formulation.
All lanes:
Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (<a href='/en-us/products/primary-antibodies/cytochrome-p450-2c19-antibody-epr6577-c-terminal-ab185213'>ab185213</a>) at 1/5000 dilution
Lane 1:
HeLa cell lysate at 10 µg
Lane 2:
293 cell lysate at 10 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated antibody at 1/1000 dilution
Predicted band size: 56 kDa
Observed band size: 52 kDa
false
Related conjugates and formulations (1)
-
Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal
Reactivity data
Product details
ab250812 is the carrier-free version of ab185213.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Cytochrome p450 2C19 contributes to the body's drug metabolism and detoxification processes. It is not part of any known enzymatic complex but plays a direct role in the metabolism of many clinically relevant drugs including proton pump inhibitors and antiplatelet medications. Through these actions the enzyme protects the body from potentially harmful effects of drugs and helps maintain metabolic homeostasis. This enzyme has genetic polymorphisms that lead to differences in drug metabolism among different individuals.
Pathways
The enzyme plays a significant role in the drug metabolism and pharmacokinetics pathways. CYP2C19 is involved in the hepatic phase I drug metabolism pathway where it metabolizes drugs into more polar excretable forms. It relates to other enzymes like CYP2C9 and CYP2D6 which together with it form the main subfamilies involved in the oxidation of a diverse range of lipophilic drugs and compounds. This allows for the extensive breakdown and unloading of various substances utilized in therapeutic contexts.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
The American journal of pathology 187:1686-1699 PubMed28618255
2017
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com